Search

Search Constraints

You searched for: Author/Creator Santarsiero, Diletta

Search Results

1. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Issue 1 (24th November 2020)

2. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Issue 1 (24th November 2020)

3. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Issue 1 (January 2022)

4. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Issue 1 (January 2022)

5. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Issue 1 (January 2022)

6. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Issue 12 (December 2022)